aTyr Pharma (NASDAQ:ATYR) Earns "Equal Weight" Rating from Wells Fargo & Company

Key Points

• aTyr Pharma received an "Equal Weight" rating from Wells Fargo, while several other analysts have downgraded their ratings recently, indicating mixed sentiment in the market.
• The company reported a loss of ($0.22) EPS for its last quarter, missing expectations and projecting an overall EPS of -0.91 for the current year.
• Institutional investors hold a significant stake in aTyr Pharma, owning 61.72% of the company's stock, with notable increases in positions by several hedge funds recently.

aTyr Pharma (NASDAQ:ATYR - Get Free Report)'s stock had its "equal weight" rating reiterated by stock analysts at Wells Fargo & Company in a research report issued to clients and investors on Monday, MarketBeat Ratings reports.

A number of other equities research analysts have also issued reports on ATYR. Cantor Fitzgerald lowered shares of aTyr Pharma from an "overweight" rating to a "neutral" rating in a research note on Monday. Wall Street Zen lowered shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Jefferies Financial Group upped their target price on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 22nd. Leerink Partners restated a "market perform" rating on shares of aTyr Pharma in a research note on Monday. Finally, HC Wainwright lowered shares of aTyr Pharma from a "buy" rating to a "neutral" rating in a research note on Monday. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $23.25.

aTyr Pharma Stock Up 4.4%

ATYR traded up $0.05 during trading hours on Monday, reaching $1.07. 43,671,642 shares of the stock traded hands, compared to its average volume of 3,797,469. The firm's fifty day simple moving average is $5.28 and its two-hundred day simple moving average is $4.37. The company has a market cap of $104.36 million, a price-to-earnings ratio of -1.33 and a beta of 1.01. aTyr Pharma has a fifty-two week low of $1.00 and a fifty-two week high of $7.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). As a group, analysts forecast that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

A number of hedge funds have recently made changes to their positions in the business. Octagon Capital Advisors LP raised its holdings in shares of aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock valued at $19,367,000 after buying an additional 268,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of aTyr Pharma by 126.1% during the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company's stock valued at $10,639,000 after buying an additional 1,170,276 shares during the last quarter. Woodline Partners LP bought a new stake in shares of aTyr Pharma during the fourth quarter valued at approximately $6,092,000. Millennium Management LLC raised its holdings in shares of aTyr Pharma by 334.5% during the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock valued at $4,829,000 after buying an additional 1,231,052 shares during the last quarter. Finally, Ally Bridge Group NY LLC raised its holdings in shares of aTyr Pharma by 11.0% during the first quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company's stock valued at $2,347,000 after buying an additional 77,290 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.